Carmel Diagnostics

Measuring Oxidative Stress for IVF Applications

Health Tech & Life Sciences
Active
Seed Kiryat Tiv'on, Israel Founded 2009
Last updated 2026-06-18
Total raised
$6.9M
Last: 2023-09
Stage
Seed
Founded
2009
Headcount
5
HQ
Kiryat Tiv'on, Israel
Sector
Health Tech & Life Sciences

About

Carmel Diagnostics has developed a method for measuring the oxidative stress (OS) of biological liquids, a recognized biomarker of health and disease and a key diagnostics parameter. This OS parameter is measured using thermochemiluminescence (TCL) technology. The company's lead product is focused on the process of embryo selection in in-vitro fertilization (IVF). The Fertissimo TCL Analyzer is a noninvasive embryo selection system for the IVF market, offering up to a 20% increase in successful IVF pregnancies. Effective embryo viability assessment significantly improves the success rate and reduces the risk of multiple births. Carmel Diagnostics has performed two successful proof-of-concept studies covered by peer-reviewed articles on the applications of risk stratification for patients with congestive heart failure and embryo selection in the IVF process, and is currently performing a clinical validation study for the IVF application. Carmel Diagnostics was awarded a Horizon 2020 phase-2 grant.

Funding history · 5 rounds · $6.9M total

2023-09
2017-07
Grant $3.1M
2014-08
2014-06
Grant $170K
2013-01
Grant $600K

Q&A

What is Carmel Diagnostics' primary focus?
Carmel Diagnostics focuses on measuring oxidative stress in biological liquids using thermochemiluminescence (TCL) technology, with a lead product, the Fertissimo TCL Analyzer, aimed at embryo selection in in-vitro fertilization (IVF).
What is the current employee count for Carmel Diagnostics?
Carmel Diagnostics has 1-10 employees.
When was Carmel Diagnostics founded?
Carmel Diagnostics was founded in January 2009.
What is the total amount of funding Carmel Diagnostics has raised to date?
Carmel Diagnostics has raised a total of $6,940,000 USD.
When did Carmel Diagnostics receive its most recent funding?
Carmel Diagnostics received $3,000,000 USD in September 2023.
Which organization provided a grant to Carmel Diagnostics in July 2017?
In July 2017, Carmel Diagnostics received a grant of $3,070,000 USD from EU Horizon 2020.
What is the current product stage of Carmel Diagnostics?
Carmel Diagnostics' product is currently in the clinical trial stage.
Who are the founders of Carmel Diagnostics?
The founders of Carmel Diagnostics are Cnaani Tzali, who serves as Founder & CEO, and Sergei Shnizer, who is the Co-founder & CTO.

Team · 2

Founder · Founder & CEO
LinkedIn ↗
Founder · Co-founder & CTO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportMedical DevicesDiagnostics Devices
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesConsumersDemographics & FamilyWomen
Business model
B2B

Highlights

1 PatentsVerified

Tags

laboratoriesmedical-devicesmonitoringfertilityheart-failurediagnosticsmedical-technologieswomenwomen-healthnon-invasivebiomarkersdigital-healthcaregynecologycardiologydecision-supportfemtech
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)